tbuckley/cabot-search huggingface dataset:
NIMG-67. PRE-RADIATION TUMOR PROGRESSION IMPROVES PROGNOSTIC STRATIFICATION IN GLIOBLASTOMA PATIENTS
Authors: Joshua Palmer, Gaurav Shukla, Mehri Mollaee, Dinesh Sharma, Jenna Skowronski, Deepak Bhamidipati, Colin Champ, Jon Glass, Lyndon Kim, Kevin Judy, James Evans, Christopher Farrell, David Andrews, Stephen Peiper, Wenyin Shi, Zi-Xuan Wang, Maria Werner-wasik
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is a common form of primary brain tumor with poor prognosis. There are few markers which direct therapy. We hypothesize that MRI evidence of tumor progression during the interval between surgical resection and initiation of radiation therapy may be associated with poorer overall survival. Patients with GBM were retrospectively reviewed between 2008-2015. Patients with pathologically confirmed GBM were included if they had undergone both a post-operative MRI and a pre-radiation treatment planning MRI. Patients with only post-operative or pre-radiation CT imaging were excluded. MGMT testing was performed on all patients. The pre-RT MRI was compared to the post-operative MRI imaging and Early Progression (EP) defined as the presence of new nodular enhancement. We compared survival between EP, no EP and MGMT methylation status using the Kaplan Meier method and log rank tests. We collected 107 patients, 87 patients met entry criteria. Of the 87 patients, 45 (52%) demonstrated EP. Median age was 59 and 58 for no EP and EP, respectively. Median KPS was 80 for both groups. Extent of resection was 10% vs 2% biopsy, 50% vs 83% STR, and 40% vs 15% GTR for no EP vs EP. Eloquent tumor location was seen in 16% (no EP) vs 27% (EP). The median survival for patients was 9.57 months (EP) vs 20.05 months (no EP) (p=0.0015). Survival based on MGMT was 15.35 months (unM) vs 21.86 months (M) (p=0.014). Survival based on EP and MGMT was 9.47 months (EP+unM), 11.19 months (EP+M), 19.63 months (no EP+unM) and not reached (no EP+M) (p=0.0004). EP was a common finding and a strong prognostic factor. This imaging biomarker improved stratification with MGMT methylation status. We hypothesize that EP is a harbinger of poor biology. We are performing whole genome analysis. Further validation of EP is underway.
Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)
Authors: Y. Jansen, E.A. Rozeman, L. Højberg, M. Geukes Foppen, M. Schreuer, J.V. van Thienen, L. Bastholt, H. Schmidt, J.B.A.G. Haanen, I.M. Svane, A.M. Arance Fernandez, C. Blank, B. Neyns
Journal: Annals of Oncology (2016)
PDCT-13. GUIDELINES FOR RESPONSE ASSESSMENT IN MEDULLOBLASTOMA AND OTHER LEPTOMENINGEAL SEEDING TUMORS: A REPORT FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY (RAPNO) WORKING GROUP
Authors: Katherine Warren, Julie Harreld, Marc Chamberlain, Gilbert Vezina, Monika Warmuth-Metz, Katja von Hoff, Roger Packer, Alba A. Brandes, Moshe Reiss, Stewart Goldman, Michael Fisher, Tina Young Poussaint, Ian Pollack, Michael Prados, Patrick Wen, Susan Chang, Christelle Dufour, David Zurakowski, Rolf-Dieter Kortman, Mark Kieran
Journal: Neuro-Oncology (2016)

Lack of standard response criteria in clinical trials for patients with medulloblastoma and other seeding tumors poses a significant issue; retrospective evaluations have shown significant discordance between local centers and central reviewers regarding residual disease and presence of metastatic disease. An international working group consisting of adult and pediatric neuro-oncologists, radiologists, radiation oncologists, and neurosurgeons was established to develop consensus recommendations for response assessment that can be prospectively evaluated in clinical trials, with the goal of achieving more reliable risk stratification and uniformity across clinical trials. METHODS: Current practices and literature review were performed to identify major confounding issues in medulloblastoma and justify subsequently developed recommendations, and consensus was reached after discussion. RESULTS: These recommendations apply to both adult and pediatric patients with medulloblastoma and other seeding tumors. Response should be assessed using MR imaging (brain and spine), CSF cytology, and neurologic examination. Clinical imaging standards with minimum mandatory sequence acquisition that optimizes detection of leptomeningeal metastases were defined. The baseline brain MRI for clinical trials should be performed within 72 hours of surgery, and repeated 2-3 weeks later if extensive parenchymal postsurgical changes obscure residual tumor. Central review should occur prior to inclusion in treatment cohorts to ensure appropriate risk stratification and cohort inclusion. The pre-operative spine MRI may be considered baseline when feasible to obtain; if not feasible or of poor quality, it should be repeated within 72 hours post-operatively. Baseline assessment for leptomeningeal disease should include neurologic examination, pre- and post-contrast MRI, and CSF cytology/flow cytometry. Response assessment should be done bi-monthly for most-clinical trials, but can be adapted based on scientific rationale. CONCLUSIONS: Consensus recommendations and response definitions for patients with medulloblastomas and other seeding tumors have been established; as with other RANO recommendations, these need to be prospectively validated in clinical trials.
FLAG-IM (Fludarabine, Ara-C, G-CSF, Idarubicin, Mylotarg) Is an Effective Salvage Regimen Producing High Rates of Remission (CR+CRi) in Relapsed/Refractory AML.
Authors: Sagun D. Goyal, Geoffrey L. Uy, Kristan M. Augustin, Lindsay Hladnik, Camille N. Abboud, Amanda F. Cashen, Peter Westervelt, John F. DiPersio, Ravi Vij
Journal: Blood (2007)
A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)
Authors: L.V. Sequist, I. Anderson, T.M. Bauer, N. Demars, E. Felip, N. Frost, W. Harb, L. Horn, R.M. Huber, A.J. Kudla, J. Lee, S. Mathews, R. Mehra, J. Nieva, M. Perol, F. Shepherd, A. Spira, A. Czibere
Journal: Annals of Oncology (2016)
LSTあるいはVLST,血管顕微無症状血栓,Multiple Inter-strut Hollowあるいはステント周囲対比染色と関連する良好なマーカーはどちらか?
Authors: Mori Naoki, Nishino Masami, Okamoto Naotaka, Tanaka Akihiro, Kikuchi Atsushi, Masaki Takeshi, Nakamura Daisuke, Yoshimura Takahiro, Lee Yasuharu, Taniike Masayuki, Makino Nobuhiko, Katoh Hiroyasu, Egami Yasuyuki, Shutta Ryu, Morita Hisaki, Tanouchi Jun, Yamada Yoshio
Journal: Circulation (2011)
PREVENTION OF TUBERCULOSIS.
Authors: E. B. BORLAND
Journal: JAMA (1896)

Under the light of recent investigations, the old theory of inherited tuberculosis is at best questionable. Congenital tuberculosis is comparatively infrequent. The so-called hereditary predisposition is now known to be general debility, which may arise from many causes. Any weakling has this predisposition, no difference what degree of health his parents enjoyed. All weak persons, especially the young, are liable to contract tuberculosis, if the three essential factors of infection are present, viz., debility, abrasions and bacilli.  The three essential factors of infection.  —In the convalescence of typhoid fever, for example, we have two out of the three essential factors of infection. The same factors are present in the convalescence of measles and whooping cough, viz., debility and abrasions of the mucous membranes. The third essential factor of infection is easily supplied by the millions of tubercle bacilli which can be found in almost every public building, hospital ward, railway
Psychiatric Genomics and Mental Health Treatment: Setting the Ethical Agenda
Authors: Camillia Kong, Michael Dunn, Michael Parker
Journal: The American Journal of Bioethics (2017)

Realizing the benefits of translating psychiatric genomics research into mental health care is not straightforward. The translation process gives rise to ethical challenges that are distinctive from challenges posed within psychiatric genomics research itself, or that form part of the delivery of clinical psychiatric genetics services. This article outlines and considers three distinct ethical concerns posed by the process of translating genomic research into frontline psychiatric practice and policy making. First, the genetic essentialism that is commonly associated with the genomics revolution in health care might inadvertently exacerbate stigma towards people with mental disorders. Secondly, the promises of genomic medicine advance a narrative of individual empowerment. This narrative could promote a fatalism towards patients' biology in ways that function in practice to undermine patients' agency and autonomy, or, alternatively, a heightened sense of subjective genetic responsibility could become embedded within mental health services that leads to psychosocial therapeutic approaches and the clinician-patient therapeutic alliance being undermined. Finally, adopting a genomics-focused approach to public mental health risks shifting attention away from the complex causal relationships between inequitable socio-economic, political, and cultural structures and negative mental health outcomes. The article concludes by outlining a number of potential pathways for future ethics research that emphasizes the importance of examining appropriate translation mechanisms, the complementarity between genetic and psychosocial models of mental disorder, the implications of genomic information for the clinician-patient relationship, and funding priorities and resource allocation decision making in mental health.
Professional football may be linked to brain injuries usually seen in boxing
Authors: Nigel Hawkes
Journal: BMJ (2017)

Playing soccer at a high level may lead to the same kind of brain injuries as boxing, postmortem studies at the Institute of Neurology in London have found.1

The brains of six dead male footballers, all of whom had dementia, were examined, and four showed signs of chronic traumatic encephalopathy (CTE), a characteristic pattern of damage that is nearly universal in the brains of boxers but uncommon in the general population.

Although the numbers were small the results suggested that repeated heading of the ball, together with other head impacts from collisions and falls, can cause damage leading to dementia. But the analysis was complicated because the six brains also all showed changes characteristic of Alzheimer’s disease.

“CTE has been found in 100% of the brains of boxers, but only 6% of the general population,” Helen Ling, lead author of the study, told a briefing at the Science Media Centre in London. …
MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
Authors: Erica H. Bell, Peixin Zhang, Barbara J. Fisher, David R. Macdonald, Joseph P. McElroy, Glenn J Lesser, Jessica Fleming, Arup Chakraborty, Ziyan Liu, Aline Paixao Becker, Denise Fabian, Kenneth D. Aldape, Lynn S. Ashby, Maria Werner-Wasik, Eleanor M Walker, Jean-Paul Bahary, Young Kwok, Michael Yu, Nadia N. Laack, Christopher J Schultz, Heidi J. Gray, H. Ian Robins, Minesh P. Mehta, Arnab Chakravarti
Journal: Neuro-Oncology (2016)

This study sought to determine the proportion of patients with MGMT promoter methylation within NRG Oncology/RTOG 0424 and its prognostic significance in the setting of high-risk low-grade glioma treated with radiation and temozolomide. The MGMT-STP27 prediction model was used to calculate MGMT promoter methylation status from Illumina HM-450K data. Univariable (UVAs) and multivariable analyses (MVAs) were performed using the Cox proportional hazard model, to analyze the effect of MGMT status on survival outcomes. Patient pretreatment characteristics were included as covariates in MVAs. Of all the eligible patients in NRG Oncology/RTOG 0424, 75 (58.1%) have MGMT status available: 57 (76.0%) methylated and 18 (24.0%) unmethylated. Between the two groups, no significant difference was observed on age and performance status at baseline. Majority (72.2%) of the unmethylated patients had astrocytoma as opposed to oligoastrocytoma/oligodendroglioma, whereas 40.4% of methylated patients had astrocytoma. Upon UVAs, MGMT methylation was significantly correlated with better OS and PFS. Upon MVAs, the statistical significance was maintained, with a HR=2.89 (p=0.009) for OS and a HR=2.88 (p=0.003) for PFS. MGMT promoter methylation, as determined by the MGMT- STP27 model, was an independent prognostic biomarker of high-risk low-grade glioma treated with temozolomide and radiation. The large percentage of methylated patients in this study may be a contributing factor to the high survival rates reported previously relative to historical controls. Importantly, this is the first study to validate the prognostic significance of MGMT promoter methylation in temozolomide-treated grade II glioma patients using rigorous MVAs with prospectively-collected, well-annotated clinical data. Analysis of the prognostic significance of MGMT promoter methylation relative to IDH and 1p/19q status is ongoing. FUNDING: U10CA21661, U10CA180868, U10CA180822, and U10CA37422 (NCI) & Merck & Co. Also, R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01 (NCI), Brain Tumor Funders Collaborative Grant, and The Ohio State University CCC (all to AC).
Focalized treatment strategy for patients with 1 to 5 breast cancer brain metastasis: a retrospective study of 70 patients treated with surgery or stereotactic radiosurgery
Authors: L. Eberst, M. Morelle, M.-P. Sunyach, E. Jouanneau, P. Heudel, O. Tredan, R. Tanguy, I.L. Ray-Coquard, T. Bachelot
Journal: Annals of Oncology (2016)
A first-in-human (FIH) phase I/II, dose escalation, pharmacokinetic (PK) study to assess the safety and tolerability of VAL-201 in patients with advanced prostate cancer (APC) and other advanced solid tumours
Authors: R.S. Kristeleit, R.E. Miller, L.E. Sellers, N.F. Brown, P. Gougis, A. Boyd, G. Morris, H. Payne, S. Hughes, M. Forster, M. Linch
Journal: Annals of Oncology (2016)
Effect of baseline metabolic aberrations in men with locally advanced/metastatic prostate cancer treated with ADT on time to disease progression, prostate cancer specific and all cause death
Authors: D. Crawley, M. van Hemelrijck, S. Chowdhury, N. James, C. Gilson, M. Spears, M.R. Sydes, S. Rudman
Journal: Annals of Oncology (2016)
A Novel Modified Tissue-Type Plasminogen Activator(t-PA), E6010, Reduces Reperfusion Arrhythmias Induced After Coronary Thrombolysis. Comparison of Native t-PA and Urokinase.
Authors: Mamoru Saito, Suguru Suzuki, Yoshiki Yui, Chuichi Kawai
Journal: Circulation (1995)

The aim of this study was to compare the effects of a novel modified tissue-type plasminogen activator (t-PA), E6010, to those of native t-PA and urokinase on reperfusion arrhythmias (premature ventricular complexes: PVC) and the mortality rate after coronary thrombolysis. The frequency of PVC and the mortality rate were evaluated in anesthetized dogs which had 1-, 3- or 6-h-old thrombi induced by a copper coil in the coronary artery. Thrombolytic treatment with a bolus intravenous (iv) injection of E6010 was compared with the continuous iv administration of native t-PA or urokinase. The frequency of PVC was significantly lower in the E6010 group than in the native t-PA and urokinase groups (P<0.05). The mortality rate in the E6010 group (0.0%) tended to be lower than those in the native t-PA group (10.7%) and the urokinase group (7.1%). These results indicate that the bolus iv injection of E6010 reduced both PVC and the mortality rate, compared with the continuous iv administration of native t-PA or urokinase for coronary thrombolysis; Therefore, E6010 may have beneficial effects in prehospital thrombolysis.
High BAALC Expression in Cytogenetically Normal Acute Myeloid Leukemia Strongly Correlates with Adverse Markers Such As RUNX1mut, MLL-PTD and FLT3-ITD and Is Useful for Disease Monitoring
Authors: Simone Weber, Tamara Alpermann, Christiane Eder, Frank Dicker, Sabine Jeromin, Alexander Kohlmann, Annette Fasan, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger
Journal: Blood (2012)
BMET-17. THE PROGNOSTIC ROLE OF TUMOR VOLUME IN THE OUTCOME OF PATIENTS WITH SINGLE BRAIN METASTASIS AFTER STEREOTACTIC RADIOSURGERY
Authors: Elizabeth Bennett, Michael Vogelbaum, Gene Barnett, Lilyana Angelov, Samuel Chao, Erin Murphy, Jennifer Yu, John Suh, Xuefei Jia, Paul Elson, Glen Stevens, Manmeet S. Ahluwalia, Alireza Mohammadi
Journal: Neuro-Oncology (2016)

Patients with single brain metastasis (SBM) tend to have better outcome after stereotactic radiosurgery (SRS). Current prognostic indices are based on performance status, number of lesions, and systemic disease progression. We analyzed our large SRS database to evaluate other possible prognostic factors in patients with SBM. 584 patients with SBM that were treated with SRS at our institution (2000-2012) was used for this study. Study endpoints were overall survival (OS), distant (brain) and local progression free survival (DPFS and LPFS respectively) from SRS. Tumor volume was stratified by a cut point of 1.8 cm. Multivariable analysis was performed to develop prognostic ­models. Overall, 87% of patients died during follow-up with a median OS of 10.8 months. 196 patients (36.7%) had distant progression and 102 patients (19.2%) had local progression. Other than Graded Prognostic Assessment (GPA), neurological symptoms (P=0.01) and tumor volume (P =0.021) were associated with OS. For DPFS, GPA and tumor volume (P=0.011) were prognostic, and we were able to define two prognostic groups: “favorable” (median DPFS = 14.2 months), and “unfavorable” (median DPFS = 8.9 months) (P <.001). Likewise, for LPFS, GPA, neurologic symptoms (P=0.011), tumor volume (P=0.036) and interval from primary cancer to BM (P=0.046) were found to be significant, and defined into three groups: “unfavorable” (median LPFS = 6.1 months), “intermediate” (median LPFS = 10.9 months) and “favorable” (median LPFS = 15.0 months) (P <.001). This is the largest series of patients with SBM treated with SRS analyzed for OS, LPFS, and DPFS. Other than traditional prognostic models like GPA, tumor volume had a significant role in all three outcomes for SBM. Symptomatic SBM (for OS and LPFS) and interval from primary cancer (for LPFS) were other prognostic factors.
Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): Safety, efficacy and survival outcomes from the South Australian registry
Authors: A. Ayoola, S. Vantandoust, A. Roy, T.J. Price, M. Kitchener, D. Roder, S. Quinn, G. Kichenadasse, C. Piantadosi, R. Padbury, C. Karapetis
Journal: Annals of Oncology (2016)
Prognostic value of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and mean platelet volume (MPV) in patients with colorectal carcinoma [Izmir Oncology Group (IZOG) study]
Authors: U. Oflazoglu, A. Alacacioglu, I. Kundak Somali, M. Yuce, M.A. Buyruk, U. Varol, T. Salman, H. Taskaynatan, Y. Yildiz, Y. Kucukzeybek, I. Oztop, M.O. Tarhan
Journal: Annals of Oncology (2016)
The TP53 Codon72 Polymorphism Is Associated with TP53 Mutations in Chronic Lymphocytic Leukemia
Authors: Vera Grossmann, Valentina Artusi, Susanne Schnittger, Frank Dicker, Sabine Jeromin, Lucia Boeck, Torsten Haferlach, Claudia Haferlach, Wolfgang Kern, Alexander Kohlmann
Journal: Blood (2011)
Association between early pregnancy vitamin D status and changes in serum lipid profiles throughout pregnancy
Authors: Jaqueline Lepsch, Ilana Eshriqui, Dayana Rodrigues Farias, Juliana S. Vaz, Amanda C. Cunha Figueiredo, Amanda Rodrigues Amorim Adegboye, Alex Brito, Rana Mokhtar, Lindsay H. Allen, Michael F. Holick, Gilberto Kac
Journal: Metabolism (2017)
Changes in Gene Expression Profiles in Patients with 5q- Syndrome Caused by Lenalidomide Treatment
Authors: Monika Belickova, Jaroslav Cermak, Jitka Vesela, Eliska Cechova, Zuzana Zemanova, Kyra Michalova, Michaela Dostalova Merkerova, Anna Jonasova
Journal: Blood (2011)
Erosive pustular dermatosis of the scalp: Clinical, trichoscopic, and histopathologic features of 20 cases
Authors: Michela Starace, Camilla Loi, Francesca Bruni, Aurora Alessandrini, Cosimo Misciali, Annalisa Patrizi, Bianca Maria Piraccini
Journal: Journal of the American Academy of Dermatology (2017)
Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial
Authors: Uwe Platzbecker, Martin Wermke, Jörgen Radke, Alexander Kiani, Franzi Seltmann, Christoph Röllig, Malte von Bonin, Brigitte Mohr, Uta Oelschlägel, Johannes Schetelig, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede
Journal: Blood (2010)
Bortezomib and Plasma Cell Leukemia.
Authors: Pellegrino Musto, Marialucia Barone, Roberto Guariglia, Giuseppe Pietrantuono, Francesca Gay, Fausto Rossini, Tommasina Guglielmelli, Vincenzo Pitini, Felicetto Ferrara, Monica Galli, Antonietta Falcone, Samantha Pozzi, Fiorella D’auria, Stefano Sacchi, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2006)
Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Authors: Richard Kelly, Louise Arnold, Stephen Richards, Anita Hill, Sandra vanBijnen, Petra Muus, Donna Dorr, Robert Brodsky, Gus Khursigara, Russell P. Rother, Peter Hillmen
Journal: Blood (2008)
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing
Authors: Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, Luca Zazzeroni, Claudia Venturi, Ilaria Iacobucci, Domenico Russo, Paola Bresciani, Mario Luppi, Michele Baccarani, Michele Cavo, Giovanni Martinelli
Journal: Blood (2014)
A systematic review and meta-analysis of the prognostic value of total cell-free DNA quantification in metastatic colorectal cancer
Authors: K.-L.G. Spindler, A.K. Boysen, N. Palisgaard, J. Johansen, J. Tabernero, P.M. Mau-Soerensen, T.F. Hansen, D. Sefrioui, B.V. Jensen, B.S. Soerensen, R.F. Andersen, C. Demuth, I. Brandslund, A. Jakobsen
Journal: Annals of Oncology (2016)
Inhibition of PI3K pathway improves anti HER2 treatment efficacy in a panel of HER2 positive gastric cancer cell lines
Authors: V. Gambardella, M.J. Llorca-Cardeñosa, J. Castillo, N. Tarazona Llavero, M. Huerta, S. Roselló Keränen, M. Ibarolla-Villava, G. Ribas, A. Gil, A. Cervantes
Journal: Annals of Oncology (2016)
Intralymphatic Injection of Autoantigen in Type 1 Diabetes
Authors: Johnny Ludvigsson, Jeanette Wahlberg, Rosaura Casas
Journal: New England Journal of Medicine (2017)

Preserved beta-cell function may improve outcomes in patients with type 1 diabetes. In this pilot trial, residual beta-cell function was preserved in six patients after direct intralymphatic injection of alum-formulated glutamic acid decarboxylase with oral vitamin D.
Monocarboxylate Transporters Play an Important Role in Aerobicglycolysis in Multiple Myeloma
Authors: Shiho Fujiwara, Naoko Wada, Yawara Kawano, Hiromichi Yuki, Yutaka Okuno, Kisato Nosaka, Hiroaki Mitsuya, Hiroyuki Hata
Journal: Blood (2012)